Toll Free: 1-888-928-9744

MorphoSys AG - Product Pipeline Review - 2014

Published: Jul, 2014 | Pages: 44 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

MorphoSys AG - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'MorphoSys AG - Product Pipeline Review - 2014', provides an overview of the MorphoSys AG's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of MorphoSys AG's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of MorphoSys AG including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of MorphoSys AG's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the MorphoSys AG's pipeline products

Reasons to buy

- Evaluate MorphoSys AG's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of MorphoSys AG in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the MorphoSys AG's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of MorphoSys AG and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of MorphoSys AG
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of MorphoSys AG and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
MorphoSys AG Snapshot 5
MorphoSys AG Overview 5
Key Information 5
Key Facts 5
MorphoSys AG - Research and Development Overview 6
Key Therapeutic Areas 6
MorphoSys AG - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pipeline Products - Partnered Products 11
Partnered Products/Combination Treatment Modalities 12
Pipeline Products - Out-Licensed Products 14
Out-Licensed Products/Combination Treatment Modalities 15
MorphoSys AG - Pipeline Products Glance 16
MorphoSys AG - Clinical Stage Pipeline Products 16
Phase II Products/Combination Treatment Modalities 16
Phase I Products/Combination Treatment Modalities 17
MorphoSys AG - Early Stage Pipeline Products 18
Preclinical Products/Combination Treatment Modalities 18
Discovery Products/Combination Treatment Modalities 19
MorphoSys AG - Drug Profiles 20
MOR-208 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
NOV-3 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
MOR-202 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
BI-1 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
CNTO-5 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
NOV-7 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
PFE-1 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Monoclonal Antibodies For MRSA Infections 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Monoclonal Antibody for Oncology 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
MOR-206 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
MorphoSys AG - Pipeline Analysis 32
MorphoSys AG - Pipeline Products by Target 32
MorphoSys AG - Pipeline Products by Route of Administration 33
MorphoSys AG - Pipeline Products by Molecule Type 34
MorphoSys AG - Pipeline Products by Mechanism of Action 35
MorphoSys AG - Recent Pipeline Updates 36
MorphoSys AG - Dormant Projects 40
MorphoSys AG - Discontinued Pipeline Products 41
Discontinued Pipeline Product Profiles 41
MOR-203 41
MOR-101 41
MOR-102 41
MorphoSys AG - Locations And Subsidiaries 42
Head Office 42
Appendix 43
Methodology 43
Coverage 43
Secondary Research 43
Primary Research 43
Expert Panel Validation 43
Contact Us 44
Disclaimer 44
List of Tables
MorphoSys AG, Key Information 5
MorphoSys AG, Key Facts 5
MorphoSys AG - Pipeline by Indication, 2014 8
MorphoSys AG - Pipeline by Stage of Development, 2014 9
MorphoSys AG - Monotherapy Products in Pipeline, 2014 10
MorphoSys AG - Partnered Products in Pipeline, 2014 11
MorphoSys AG - Partnered Products/ Combination Treatment Modalities, 2014 12
MorphoSys AG - Out-Licensed Products in Pipeline, 2014 14
MorphoSys AG - Out-Licensed Products/ Combination Treatment Modalities, 2014 15
MorphoSys AG - Phase II, 2014 16
MorphoSys AG - Phase I, 2014 17
MorphoSys AG - Preclinical, 2014 18
MorphoSys AG - Discovery, 2014 19
MorphoSys AG - Pipeline by Target, 2014 32
MorphoSys AG - Pipeline by Route of Administration, 2014 33
MorphoSys AG - Pipeline by Molecule Type, 2014 34
MorphoSys AG - Pipeline Products by Mechanism of Action, 2014 35
MorphoSys AG - Recent Pipeline Updates, 2014 36
MorphoSys AG - Dormant Developmental Projects,2014 40
MorphoSys AG - Discontinued Pipeline Products, 2014 41 



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $1500
Multi User - US $3000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify